Apoptosis inducer 7
Based on 1 publication(s) in Google Scholar
Apoptosis inducer 7 (Compound 5I) induces apoptosis in cancer cells. Apoptosis inducer 7 inducrs cleavage of PARP, caspases, down-regulation of anti-apoptotic protein c-Flip and up regulation of pro-apoptotic protein Noxa. Apoptosis inducer 7 exhibits antitumor activity.
For research use only. We do not sell to patients.
- CAS No.: 2252278-57-0
- Formula: C49H68N2O7
- Molecular Weight:797.07
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Apoptosis inducer 7
More
Biological Activity
Description
In Vitro
Apoptosis inducer 7 (Compound 5I) (0.098-50 μM, 96 hours; human tumor cell lines) exerts the most potent antitumor activities against human cancer cell lines[1].
Apoptosis inducer 7 (Compound 5I) induces apoptosis in HCT-116 cells, and the apoptosis induction is related to the downregulation of anti-apoptotic protein c-Flip and upregulation of pro-apoptotic protein Noxa[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Human breast cancer MDA-MB-231 cells, human lung cancer A549 cells, human colorectal cancer HCT-116 cells, human liver cancer HepG-2 cells and one non-tumor human breast epithelial MCF-10A cells.
-
Concentration:0.098-50 μM
-
Incubation Time:96 hours
-
Result:Inhibited with IC50 values of 0.22, 0.15, 0.42, 0.14 and 1.03 μM for MDA-MB-231, A549, HCT-116, HepG-2 and MCF-10A, respectively.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 0.75 and 1.0 μM
-
Incubation Time:24 hours
-
Result:More than 40% of the cells were detected in the sub G1 phase.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 0.75 and 1.0 μM
-
Incubation Time:24 hours
-
Result:Induced cleavage of PARP, caspases and decreased the levels of c-Flip and HDAC3 proteins.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KARPAS-422 subcutaneous xenograft in mice[1]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; three times a week, for 14 days.
-
Result:Inhibited the tumor growth with an inhibition rate of 62.3%, without significant body weight loss.
Chemical Information
-
CAS No. 2252278-57-0
-
Molecular Weight 797.07
-
Formula C49H68N2O7
-
SMILES
C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@@]3([H])C[C@](C)(CC4)C(OCC5=CC=CC=C5)=O)C)C)=O)([H])[C@@]6([C@@](C(C)(C(/C(C6)=C/C(NC7CCN(CC7)C(OC(C)(C)C)=O)=O)=O)C)([H])CC1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Bone Res
The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. [Abstract]2024 Aug 27;12(1):47. PMID: 39191757
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)